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Clinicopathological features and outcome for dogs with mast cell
tumors and bone marrow involvement
Abstract
BACKGROUND: Mast cell tumors (MCTs) with bone marrow (BM) involvement are poorly
documented in dogs and are associated with a poor prognosis. Successful treatment strategies have not
been described. HYPOTHESIS: Clinicopathologic findings of affected dogs are not specific.
Administration of lomustine or imatinib is beneficial. ANIMALS: Fourteen dogs with MCT and BM
involvement. METHODS: Clinical and laboratory evaluations were performed in each dog on admission
and during follow-up. All dogs received prednisone. Additionally, 8 dogs received lomustine and 3 dogs
received imatinib. Imatinib was administered if tumor-associated tyrosine kinase KIT was aberrant.
RESULTS: On admission, 11 dogs had a single cutaneous nodule and 3 dogs had multiple nodules.
Involvement of regional lymph nodes, liver, or spleen was observed in each dog. BM infiltration with
mast cells (MCs) was observed in all dogs. On CBC, nonregenerative anemia, leukopenia, or
thrombocytopenia was common. Four dogs had circulating MCs. Increased alkaline phosphatase or
alanine transferase activity was observed in 12 and 10 dogs, respectively. Treatment with lomustine
induced partial remission in 1 of 8 dogs. Median survival time was 43 days (range, 14-57). Dogs on
imatinib experienced complete remission. Two dogs survived for 117 and 159 days, and the third was
alive after 75 days. Dogs treated symptomatically did not improve and were euthanized after 1, 14, and
32 days. CONCLUSIONS AND CLINICAL IMPORTANCE: A combination of clinical and laboratory
evaluation helps in identifying dogs with MCT and BM infiltration. Administration of lomustine is not
helpful in affected dogs. The beneficial effect of imatinib warrants further investigation.
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CLINICO-PATHOLOGICAL FEATURES AND OUTCOME FOR 
CANINE MAST CELL TUMOR WITH BONE MARROW 
INVOLVEMENT.  
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Background: Canine mast cell tumor (MCT) with bone marrow (BM) involvement is 
scarcely documented and is associated with a poor prognosis. Successful treatment 
strategies have not been described. 
Hypothesis: Clinico-pathologic findings of affected dogs are not specific. 
Administration of lomustine or imatinib is beneficial. 
Animals: 14 dogs with MCT and BM involvement. 
Methods: Clinical and laboratory evaluations were performed in each dog on admission 
and during follow-up. All dogs received prednisone. Additionally, 8 dogs received 
lomustine, and 3 imatinib. Imatinib was administered if the tumor-associated tyrosine 
kinase KIT was aberrant. 
Results: On admission 11 dogs had a single cutaneous nodule while 3 had multiple 
nodules. Involvement of regional lymph nodes, liver or spleen was observed in each 
case. BM infiltration with mast cells was observed in all dogs. On blood work, 
nonregenerative anemia, leukopenia or thrombocytopenia were common. Four dogs had 
circulating mast cells. Increased alkaline phosphatase and alanine transferase were 
observed in 12 and 10 dogs, respectively. Treatment with lomustine induced partial 
remission in one out of 8 dogs. Median survival time was 43 days (range, 14-57). Dogs 
on imatinib experienced complete remission. Two dogs survived 117 and 159 days, and 
the third is alive after 72 days. Dogs treated symptomatically did not improve and were 
euthanized after 1, 14 and 32 days. 
Conclusions and Clinical Importance: A combination of clinical and laboratory 
evaluation helps identifying dogs with MCT and BM infiltration. Administration of 
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lomustine is not helpful in affected dogs. The beneficial effect of imatinib warrants 
further investigation. 
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Canine mast cell tumors (MCTs) have an extremely variable biologic behaviour, 
ranging from strictly benign cutaneous masses to metastatic disease.1-3 While dogs with 
cutaneous MCTs often harbour no symptoms, in the case of visceral and bone marrow 
(BM) involvement patients may suffer from serious disease.4,5 Symptoms are mainly 
related to the release of mast cell (MC) mediators, including histamine, heparin and 
other vasoactive amines, which can lead to localized flushing, gastrointestinal signs, 
generalized itching, vasodilatory shock and anaphylaxis.6 Moreover, the MC infiltration 
itself may cause organomegaly, impairment of organ function and, in the case of BM 
involvement, pancytopenia.4
MCs are rarely observed in BM cytology samples obtained from healthy dogs;4,7 
however, they may be increased in dogs with diseases other than MCTs, such as 
inflammatory skin diseases, enteritis, pancreatitis, heartworm disease and parvovirus 
infection.8 In MCT, the presence of neoplastic BM infiltration is rare, and it is generally 
more common in dogs bearing an aggressive (grade III) primary cutaneous tumor.3,4,9-11 
In a recent retrospective study, the incidence of BM infiltration at initial staging in dogs 
with cutaneous MCTs was 2.8%.12 An additional retrospective study13 focused on the 
incidence of BM disorders in dogs. Among BM samples, metastatic MCs were found in 
0.4% of specimens.13 
Pertinent literature has emerged in the last decade with regard to therapeutic strategies 
for canine MCTs, covering several issues such as surgery, radiation therapy, 
chemotherapy, electrochemotherapy and photodynamic therapy.3,14-17 Among 
chemotherapeutic drugs, lomustine and vinblastine are considered the most active 
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agents against neoplastic MCs.18-22 In recent years, the use of targeted drugs in the 
treatment of MCT has also been proposed.
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23,24  
MCs are derived from hematopoietic precursor cells that reside in BM and peripheral 
blood. The process of MC differentiation is influenced by cytokines and by a stem cell 
factor (SCF) which represents the ligand for KIT, a trans-membrane tyrosine kinase 
(TK) receptor encoded by the proto-oncogene c-kit and constitutively expressed by 
MCs.25 In recent years, c-kit has been implicated in the pathogenesis of canine MCTs.25 
In about 15% to 50% of canine patients with MCT, c-kit mutations, especially in exon 
11, have been detected and are considered responsible for ligand-independent KIT 
phosphorylation and to the subsequent autonomous growth of MCs.24-28,41,42 
Additionally, a significant association of c-kit mutations with higher histologic grade 
and worse prognosis has been shown in dogs with MCTs.25,28,42 Recent studies have also 
suggested that KIT autophosphorylation leads to aberrant cytoplasmic localization of 
KIT, as compared with MCTs that lack mutations and have normal perimembrane 
protein localization.34,42 Furthermore, aberrant KIT protein localization has been found 
significantly associated with increased cellular proliferation.42
Recently, a number of potent TK inhibitors have been developed, with imatinib 
mesylate (from now on called imatinib) being among the most explored in humans.30 
Imatinib directly inhibits the catalytic activity of KIT by interfering with the binding of 
ATP, thereby blocking TK phosphorylation and downstream signalling.30 Until now, 
few studies have investigated the efficacy of imatinib for the treatment of MCTs in 
veterinary medicine, and most of them have been performed in cats or in canine cell 
culture lines.31-34 The optimum drug dosage and duration of treatment await to be 
investigated in dogs. Conversely, another TK inhibitor (SU11654) has shown 
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antiproliferative effects in canine MCT biopsies and measurable responses in dogs with 
different tumors, including MCTs.
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A review of the literature failed to reveal studies on treatments specifically aimed to 
eradicate MCTs with BM infiltration. Currently, disease progression in dogs with BM 
involvement is rapid and associated to a fatal outcome in most cases.4 Given the fact 
that cytopenias are common in affected dogs, the use of chemotherapy becomes more 
difficult and needs to be carefully balanced against its side effects on BM cell 
progenitors.  
In light of this premise, primary aims of this study were to describe the clinico-
pathological features of canine MCT with BM infiltration and the clinical outcome of 
affected dogs treated with prednisone, lomustine or imatinib. Furthermore, the 
antitumoral activity of the above mentioned therapeutic agents and the development of 
toxicity were assessed in treated dogs. 
 8
Materials and methods 109 
110 
111 
112 
113 
114 
115 
116 
117 
118 
119 
120 
121 
122 
123 
124 
125 
126 
127 
128 
129 
130 
131 
132 
 
Enrolment criteria 
Dogs with cutaneous MCTs, either solitary or multiple, and cytologically proven BM 
infiltration (stage IV based on the World Health Organization system for canine 
MCTs)35 were eligible for recruitment. Dogs with second malignancies as well as those 
with concurrent non neoplastic disorders, possibly contributing to systemic reactive 
mastocytosis,8 were excluded. In addition, treatment with either chemotherapy or 
radiation therapy in the preceding 6 months was not allowed. Finally, dogs were 
excluded from the study if they did not undergo complete staging work-up. 
Initial staging procedure included history and physical examination, complete blood cell 
count (CBC) with differential, serum biochemistry profile, liver function tests (pre- and 
post-prandial bile acids), coagulation profile (activated partial thromboplastin time 
[aPTT], prothrombin time [PT], plasma fibrinogen concentration), urinalysis (including 
protein to creatinine urinary ratio), cytological evaluation of the cutaneous nodule(s) 
and regional lymph node(s), three-dimensional measurement of the cutaneous nodule(s), 
thoracic radiographs (three views), abdominal ultrasound, fine needle aspirates of liver 
and spleen, and of BM obtained from the iliac crest. 
Regarding visceral involvement, liver and spleen were considered metastatic if 
cytologic samples showed sheets or clusters of MCs. Isolated MCs were considered 
neoplastic if atypical on morphology or in the case of aberrant (cytoplasmatic) KIT 
(CD117) expression. 
There is no current published information for determining when to consider the BM 
metastatic, and a clear cut-off level of marrow MCs has not been established. According 
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to a previous study,4 BM was considered infiltrated if MCs were >10 per 1000 
nucleated cells. In a more recent paper, BM was considered metastatic if >3-5% of all 
nucleated cells (ANC) were identified as MCs on cytology smears.
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21 Therefore, for the 
diagnosis of BM involvement to be made with confidence, we arbitrarily decided that 
MCs had to represent >10% of ANC in cytologic smears or, if atypical, >5% of ANC. 
Slides from each BM aspirate were stained with May Grünwald Giemsa (MGG) and 
examined for the presence of MCs. The number of MCs was expressed as a percentage 
of the total count of ANC. 
In selected cases (specifically in those dogs whose owners considered targeted therapy) 
an antibody against KIT receptor (CD117) was applied to cytological samples of BM, to 
evaluate the pattern of KIT expression in neoplastic MCs. Briefly, air dried BM smears 
were post-fixed in acetone and incubated overnight with a rabbit anti-human CD117 
polyclonal antibodya (1:100); a streptavidin-biotin labelling systema was used for 
immuno-labelling, and reaction was visualized with diaminobenzidine. A modified 
MGG stain (May-Grünwald solution for 1 min, Giemsa solution diluted 1 drop/cc for 5 
min) was used as counter-stain instead of haematoxylin, to better differentiate MCs 
from immature myeloid cells which can also express CD117.  
 
Treatment designs 
At the time of the investigation, treatment with imatinib was very expensive, therefore 
dogs were not randomly assigned to treatment groups. Rather, treatment group 
assignment was made on the basis of owner cost concern as follows: single-agent 
prednisoneb, lomustine and prednisone, or imatinib and prednisone. Regardless of the 
chosen treatment, all dogs received supportive care with the oral administration of H1 
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(chlorpheniramine)c and H2 (ranitidine)d antihistamine blockade. Prednisone was 
administered at a dosage of 20 mg/m
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2 twice daily; this dose was gradually tapered and 
discontinued over 24 weeks. Drugs were started after staging work-up was completed. 
All owners gave written informed consent. 
Dogs receiving prednisone only were re-evaluated monthly by means of CBC, serum 
biochemistry, BM examination and abdominal ultrasound until death or euthanasia. 
Lomustinee was administered orally at the dose of 60 mg/m2 once every 28 days. Due to 
possible myelosuppression and hepatic cumulative toxicity, CBC as well as liver 
parameters and liver function tests were repeated 14 days after treatment and right 
before the next administration. The other laboratory tests as well as the complete 
staging work-up were repeated monthly. The lomustine dose was maintained for the 
duration of the study unless toxicity occurred or disease progressed. 
Imatinibf was administered orally at the dose of 4.4 mg/kg (2 mg/lb) during the first 
morning meal. In cats, imatinib mesylate has been administered at dosages ranging from 
5 to 10 mg/kg;32 however, no such information has been reported in the canine species. 
According to preclinical toxicology studies conducted in dogs, imatinib administered 
orally at dosages ≥10 mg/kg was associated to gastrointestinal, hepatic and hematologic 
toxicity, whereas 3 mg/kg appeared to be safe.36 Considering the above, we decided to 
treat dogs at 4.4 mg/kg. Since tumoral expression of the c-kit gene product was required 
for this group of animals, KIT expression (including both intensity and localization) was 
established at baseline evaluation for each dog treated with imatinib. Dogs were treated 
at least for one month before the evaluation of efficacy and safety took place. If 
treatment with imatinib was beneficial, then dogs were allowed to continue treatment 
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until progression of disease or death. Complete staging work-up was repeated monthly, 
whereas CBC and serum biochemistry were repeated biweekly.  
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Response criteria 
To evaluate response, clinical, radiological, ultrasonographic, and laboratory 
investigation were re-evaluated at the following time points: monthly during the first 6 
months, and every 3 months thereafter. Examinations were more frequent if necessary. 
Furthermore, any new masses were evaluated cytologically. The response definitions 
included: complete remission (CR), partial remission (PR), stable disease (SD) and 
progressive disease (PD). CR was characterized by disappearance of MC infiltrates in 
the involved sites at follow-up evaluation, absence of progression of systemic 
mastocytosis at other sites, active hematopoiesis with <10 MCs per 1000 nucleated cells 
in BM cytology, and full recovery of blood counts, with no detectable MCs on blood 
smears and a white blood cell count within normal limits. PR was defined as incomplete 
regression of MC infiltrates, meaning reduction of marrow MCs by ≥50% and to <10%, 
blood count recovery with the persistence of few peripheral MCs (<5%), reduction of 
hepato-splenomegaly, and ≥50% decrease in one dimension in the cutaneous nodules. 
SD was defined as <50% decrease in one dimension but no more than a 10% increase in 
any dimension of all measurable tumors, with marrow MCs reduced by <50%. PD was 
defined as ≥10% increase in any dimension of measurable tumour with no reduced or 
increased marrow MCs. Relapse was defined as cytological evidence of MCT in any 
anatomical site in dogs who have had CR, whereas relapse for animals with PR was 
defined as progression. Overall survival was defined as the time between first day of 
treatment and death. 
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Toxicity evaluation 
For Group 2 and 3, adverse events related to treatment were assessed according the 
guidelines of the Veterinary Co-Operative Oncology Group.37
In general, in dogs experiencing Grade 2 non-haematological toxicity, treatment (either 
imatinib or lomustine) was withheld until the toxicity had resolved to Grade ≤1. In dogs 
having recurrent toxicity, treatment was withheld as above and the subsequent dose was 
decreased by 25%. In dogs experiencing Grade 3-4 non-haematological toxicity, the 
study drug was withheld until the toxicity had resolved to Grade ≤1, and the dose was 
then decreased by 50%.  
For haematological toxicity, no dose reductions or interruptions were performed for 
Grade 1-2 toxicity; whereas in patients experiencing Grade 3-4 toxicity, treatment was 
withheld until toxicity was reduced to Grade ≤2, and then resumed at the same dose. If 
Grade 3-4 toxicity recurred, the treatment was withheld. 
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Patient and tumor characteristics 
Between April 2004 and August 2007, 14 dogs with previously untreated MCT and BM 
involvement were enrolled. There were 7 crossbreeds, 2 Rottweiler and one each for 
Chow Chow, Labrador retriever, Pekingese, German shepherd and Siberian husky. 
Median age was 10 years (range, 16 months-15 years). Five dogs were intact males, 5 
intact females, and 4 spayed females. Median body weight was 24.8 kg (range, 4.5-
36.1). 
Two dogs had no symptoms (substage a), whereas the remaining 12 were symptomatic 
(substage b). The duration of symptoms before referral ranged from 10 to 124 days 
(median, 21). Reported clinical signs were often vague and included lethargy in 10 
dogs, decreased appetite in 9, weight loss in 7, vomit in 4, and diarrhoea or 
polyuria/polidipsia in 2 each. Major complaint for one dog was melena, whereas 2 dogs 
showed intense generalized pruritus. Presenting clinical sign in another dog was 
straining to urinate and defecate. 
At diagnosis 11 dogs had a single cutaneous nodule whereas 3 had multiple nodules. 
MCTs were cytologically well-differentiated or of intermediate differentiation in 4 dogs 
each, or undifferentiated in 6 dogs. Regional lymph node involvement was cytologically 
confirmed in 10 dogs, furthermore hepatic and splenic involvement were evident in 11 
and 10 cases, respectively. Three dogs showed pulmonary involvement, as evidenced by 
generalized peribronchial interstitial pattern in the caudodorsal lung fields in one 
animal, and by multiple pulmonary nodules in the others, and confirmed in two cases by 
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post-mortem histopathological evaluation, and in one case by CT-guided cytological 
examination. One dog had bilateral renal involvement. 
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Examination of BM revealed infiltration of MCs in all cases, ranging from scattered 
aggregates to complete effacing of the normal hematopoietic architecture (7-85% of 
ANC). Of note, 5 dogs had normal CBC values despite BM infiltration (7-33%). 
Regarding CBCs, at initial evaluation median packed cell volume (PCV) was 32% 
(range, 12-51; reference range, 37-55). Three dogs had severe anaemia (PCV <15%), 2 
had moderate anaemia (PCV 15-20%) whereas 4 had mild anaemia (PCV >20%). 
Anemia was nonregenerative in each dog (reticulocytes <40.000/μl). Initially, median 
white blood cell count was 7.800/μl (range, 2.600-12.900; reference, 6.000-17.000). 
Moderate eosinophilia was present in 3 dogs, with median value of 2,100 eosinophils/μl 
(range, 1.950-2.350; reference, 100-1.250). In 4 cases circulating MCs were found on 
blood smear evaluation, making up 2-10% of nucleated blood cells. Thrombocytopenia 
was observed in 5 dogs (median 95.000/μl; range, 86.000-108.000; reference, 120.000-
350.000). Coagulation parameters were prolonged in 3 dogs, expressed as a 20% 
increase of PT and aPTT; however, neither of them showed concurrent 
thrombocytopenia nor increased fibrinogen concentration, excluding disseminated 
intravascular coagulation. Alkaline phosphatase (ALP) was increased in 12 dogs 
(median, 460 UI/L; range, 202-790; reference, 0-160) and alanine transferase (ALT) in 
10 dogs (median, 78 UI/L; range, 68-122; reference, 0-65). Liver dysfunction was not 
observed. Clinical and pathological features of the enrolled dogs at disease onset are 
listed in Table 1. 
 
Treatment effects and safety data 
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At the end of the study, all dogs but one were dead with a median survival time of 41 
days (range, 1-159). Response rates for all dogs are shown in Table 2. 
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Single-agent prednisone 
Three dogs received single-agent prednisone with no improvement of clinical status. All 
of them experienced PD, eventually leading to euthanasia after 1, 14 and 32 days, 
respectively. 
Lomustine and prednisone 
Additionally to prednisone, 8 dogs were treated with lomustine at 60 mg/m2. The 
median number of lomustine treatments was 1 (range, 1-2). The original protocol was 
designed to last 6 months; however, in all cases the treatment was stopped earlier due to 
PD. Clinical improvement did not occur in most cases. Case 11 achieved PR of 41 days 
duration after the first lomustine dose, but was eventually euthanized 5 days later 
following sudden worsening of the general conditions, most likely due to massive 
degranulation, as assessed by hyperalgesia, oedema of the neck and front legs, and 
massive gastrointestinal bleeding. 
Toxicity induced by lomustine was evaluated at each visit. Five dogs experienced 
marked non febrile neutropenia by the first examination, 14 days after chemotherapy 
was started (median, 800 neutrophils/μl; range, 300-1200). Among them only 2 had 
peripheral cytopenia at presentation, including anemia (n=2) and thrombocytopenia 
(n=1). With the exception of case 4, for which euthanasia was requested by the owner at 
14 days due to poor life quality, in the others treatment had to be delayed because of 
neutropenia. Unfortunately, in none of them the second dose of lomustine could be 
administered since the disease was rapidly progressive, leading to euthanasia. Three 
dogs experienced no toxicity and received the second dose of lomustine at the scheduled 
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time. With regard to the biochemical profile, elevations in ALP and ALT were present 
at diagnosis in 7 out of the 8 dogs and did not worsen during the study period. The 
median survival time for all dogs was 43 days (range, 14-57). 
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Imatinib and prednisone 
Three dogs were treated orally with imatinib at a daily dose of 4.4 mg/kg, in addition to 
prednisone. 
At presentation, the first dog had BM infiltration, with MCs accounting for 33% of 
ANC. Nonetheless, CBC showed no abnormalities. BM infiltrating MCs were round, 
highly granulated and showed marked CD117 cytoplasmatic staining. The dog 
demonstrated rapid clinical improvement with progressive disappearance of the 
preputial mass and of the metastatic inguinal lymph node, with no reported drug-related 
toxicity. A repeated abdominal ultrasound one month after initiation of therapy revealed 
a significant decrease in the size of the liver and spleen, with no MCs observed on fine 
needle aspirates in both organs. Furthermore, a BM aspirate performed at this same time 
showed a decrease of MCs from 33% to 2%, with normal CBC. Based on these 
findings, the tumor response was defined as a CR. At 44 days the tumor was still in CR, 
also based on a further BM evaluation. Despite the excellent response, 78 days after 
initial presentation the MCT on the prepuce started to grow again. On ultrasound, 
enlarged sublumbar lymph nodes and hepato-splenomegaly were detected. Furthermore, 
BM cytology showed increased MCs (35% of ANC) and peripheral mastocytemia (5%). 
Due to physical deterioration and onset of clinical signs, imatinib was stopped. Despite 
supportive care with antibiotics (enrofloxacing and amoxicillin/clavulanateh), 
antiemetics (maropitant)i, H1 (diphenhydramine)l and H2 (ranitidine) antihistamines, and 
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prednisone, the dog necessitated two hospital admissions and one blood transfusion 
over 39 days, after which euthanasia was performed. The dog survived 117 days. 
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In the second case, peripheral blood was remarkable for the presence of tri-cytopenia 
and 10% circulating MCs. The BM aspirate revealed marked decrease in erythroid, 
myeloid and megakaryocytic lineages, with MCs accounting for 85% of marrow 
cellularity and displaying strong and diffuse immunocytochemical cytoplasmic CD117 
expression (Figure 1). Imatinib was started in the dog. CR was soon achieved, as 
assessed by disappearance of the interscapular MCT, marked size reduction of the 
metastatic prescapular lymph node, and normalization of CBC. The dramatic 
improvement of the clinical picture was accompanied by a marked reduction in MC 
numbers in the BM aspirate; in fact, after one month of therapy, BM evaluation revealed 
a notable reduction in the extent of MC infiltration, with MCs representing 4% of ANC. 
Furthermore, no MCs were observed on lymph node, splenic and hepatic cytology. At 
subsequent re-evaluation (day 60), no clinico-pathologic abnormalities were observed 
with the exception of an increased number of BM MCs (11%). Because of this finding, 
at this time lomustine at 60 mg/m2, once every 28 days, was added to imatinib aiming to 
achieve a possible synergistic effect. By day 90 the dog showed normal CBC values and 
abdominal ultrasound, 1% of BM MCs and no cutaneous or regional lymph node 
relapse. CR lasted for an additional two months, after which the tumor relapsed in BM, 
spleen and liver, as assessed by cytologic evaluation (day 150). Due to pruritus and 
development of hemorrhagic diarrhoea the dog was hospitalised and supported with 
blood transfusion, diphenhydramine, ranitidine and prednisone. During the following 9 
days the disease progressed with a dramatic increase of circulating and marrow MCs 
(23 and 92%, respectively), and the dog was eventually euthanized on day 159. 
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On admission, the third dog had BM infiltrating MCs, accounting for 7% of ANC. MCs 
were highly atypical and showed aberrant KIT expression. No peripheral blood 
abnormalities were identified. The dog received daily imatinib and once monthly 
lomustine. Follow-up with physical examination, bloodwork, abdominal ultrasound, 
thoracic radiographs and BM cytology showed CR. At the time when it was reported, 
72 days after therapy was started, the dog was still being treated with imatinib and 
lomustine, showing no tumor relapse. 
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None of the dogs on imatinib required drug withdrawal or temporary interruption due to 
toxicity. Treatment was well tolerated, with no evidence of haematological or non-
haematological side effects. 
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Discussion 346 
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In agreement with previous studies,4,9-11 our findings show that MCT with BM 
infiltration is aggressive in dogs, with 13 out of 14 animals dying either of 
complications of mastocytosis or of drug-resistant disease, with a median survival time 
of 41 days. In all cases, a combination of multiorgan involvement and severe BM 
effacement contributed to death. The initial clinical signs were vague and mainly due to 
the local or systemic effects of MC mediators, and to organ infiltration. Clinical 
manifestations indicative of BM infiltration were often difficult to recognize. Indeed, 
because most dogs had more than one organ affected, non-specific signs such as 
weakness, lethargy and weight loss, made the clinical picture more complex. As a 
consequence, the hypothesis of BM involvement relied on the fact that multiorgan 
infiltration with MCs and/or peripheral blood cytopenias were observed in all dogs. 
Dogs with MC BM infiltration show a number of haematological abnormalities, 
including anaemia, thrombocytopenia, leukopenia, leukocytosis, eosinophilia and 
basophilia.4,5,12 Circulating MCs may occasionally be observed.4,8,12 Of note, 5 dogs in 
the present study showed no haematological abnormalities in spite of marked BM 
involvement (with MCs representing 7-33% of ANC). This finding has important 
clinical implications, as lack of BM examination during the staging work-up may 
underscore the number of patients harbouring BM disease, possibly leading to 
inadequate treatment. Unlike previous experiences in MCT staging, indicating no need 
for BM evaluation unless haematological abnormalities are identified,12 our results 
suggest that positive findings in BM cytologic specimens are necessary to accurately 
stage the MCT, especially when considering chemotherapy. It is well known that dogs 
with systemic disease involving liver and/or spleen have a poor outcome, and BM 
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evaluation may not add prognostic information. Nevertheless, if in a dog with systemic 
involvement standard cytotoxic chemotherapy is considered, BM evaluation may be 
necessary. Indeed, further haematological effacement may occur with myelosuppressive 
chemotherapy, thereby reducing life quality and possibly survival. Splenic and hepatic 
disease with MC infiltration is a common finding in dogs with BM mastocytosis.
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4,9-11 In 
this cohort of dogs, 13 out of 14 dogs had either liver or spleen involvement. 
Interestingly, hepatic dysfunction was not observed, as demonstrated by normal liver 
function tests. ALP and ALT were frequently elevated at presentation. However, 
because the values were stable over the study period, we believe that these elevations 
were attributable to a combination of neoplasia-induced stress leading to endogenous 
glucocorticoid release and to direct neoplastic hepatic infiltration.38 The only case with 
no hepatic or splenic involvement had pulmonary infiltration. Lung metastasis was also 
observed in two additional dogs, which is quite uncommon for canine MCT. Altogether, 
these findings emphasize the importance of thoracic radiographs in the initial work-up. 
Historically, canine MCT with BM infiltration has been considered an extremely 
aggressive disease characterized by a rapid clinical course, with limited or no treatment 
options available. In recent years, it was shown that normal MC development and 
proliferation involve the action of SCF on KIT receptors.29 The occurrence of mutation 
in the c-kit gene leads to the aberrant expression of KIT receptors which ultimately 
promote uncontrolled proliferation.26,27,41,42 Based on this finding, the identification of 
aberrant KIT expression may become a target for treatment of canine MCT. One drug 
developed to selectively inhibit TK has been assessed in dogs with different tumors.23,24 
The TK inhibitor SU11654 showed antitumor activity especially in dogs with MCT.24 
However, the issue of marrow infiltration and how to defeat it was not addressed. 
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Lomustine is an active agent for the treatment of canine MCT.3,22 In the study reported 
here, not only did lomustine not show any activity on MCs infiltrating BM, as assessed 
by rapid disease progression in all treated dogs, but its use was associated with marked 
haematological toxicity (i.e., neutropenia). Conversely, although only in three dogs, 
imatinib showed to be effective against MC BM infiltration, whereas neither single-
agent prednisone nor lomustine improved survival. In response to imatinib therapy, the 
clinical symptoms resolved, and the BM infiltrating MCs disappeared in all cases. 
While single agent prednisone may induce responses in up to 70% of dogs with 
MCTs,
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43 it is likely that imatinib partially contributed to the complete responses in 
treated cases, as the dogs receiving single-agent prednisone did not experience any 
objective response. Although the present results may support the use of imatinib for 
MCT with BM infiltration, acquired resistance to the drug can develop. In fact, in two 
cases treatment failure was observed after 78 and 150 days, respectively. During 
relapse, BM aspirates showed similar amount of MCs to the specimens collected at 
initial presentation. In human medicine, resistance to imatinib is a major concern and is 
believed to be caused by mutations in the kinase domain interfering with imatinib 
binding.39 In addition, imatinib is a substrate of P-glycoprotein, a drug efflux pump 
which is highly expressed in hematopoietic stem cells, leading to low intracellular 
concentrations of the drug.39 To address the growing problem of relapse, molecular-
targeted drugs may be coherently integrated into pre-existing therapeutic regimens, such 
as cytotoxic drugs, with the goal of overcoming resistance and enhancing antitumor 
activity through a synergistic or additive effect. In human medicine, drug combination 
strategies are often applied based on the evidence that combining the specific inhibition 
of tumor signal pathways together with more standard therapy can effectively enhance 
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anticancer activity.40 In dogs, no information is available on the interaction of novel 
anticancer drugs with other treatment modalities, and it is possible that successful long-
term treatment of MCT with BM infiltration may require a cocktail of kinase inhibitors 
and conventional chemotherapy. Although preliminary, the results obtained in two 
imatinib-treated dogs may support such strategy. In fact, the one dog that was started on 
imatinib and later had lomustine added, experienced the longest survival, whereas the 
other dog that simultaneously received imatinib and lomustine did not have any 
evidence for a systemic or BM relapse after more than two months of observation. 
Thus, a combination of imatinib, lomustine and prednisone may yield maximal benefit. 
This hypothesis needs to be tested in further clinical trials. 
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With regard to imatinib toxicity, in all treated dogs the drug was well tolerated without 
detectable side effects. Furthermore, imatinib seemed to spare normal hemopoietic cells, 
as demonstrated by effective hemopoiesis and repopulation of metastatic marrows. 
Although suggestive, this investigation has some deficiencies, such as the small number 
of animals studied and the fact that dogs were not equally distributed between 
treatments. As suggested by the literature, and confirmed by our study which spanned 
over 3 years, BM infiltration is rare in dogs with MCT and this forcedly limits the 
number of dogs available for investigation. Also, 8 dogs received lomustine while only 
3 were administered imatinib. Unfortunately, imatinib is very expensive and yet 
prohibitive for many dog owners. Future larger studies assessing the efficacy of single-
agent imatinib, with or without adjuvant chemotherapy, are thereby warranted. 
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a DakoCytomation, Glostrup, Denmark 
b Deltacortene, Bruno-Farmaceutici, Rome, Italy 
c Trimeton, Shering-Plough, Milan, Italy 
d Zantac, GlaxoSmithKline, Verona, Italy 
e Prava, Bristol-Myers Squibb, Baar, Switzerland 
f Glivec, Novartis Europharm Limited, Horsham West Sussex, United Kingdom 
g Baytril, Bayer HealthCare, Milan, Italy  
h Synulox, Pfizer, Rome, Italy 
i Cerenia, Pfizer, Rome, Italy 
l Benadryl, Johnson & Johnson, New Jersey, USA 
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Figure 1. a. Case 13: BM: myelophthysis; b. diffuse immunocytochemical cytoplasmic 
CD117 expression. 
 
 
